Pneumonia

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Retrieved on: 
Sunday, March 19, 2023
Failure mode and effects analysis, Non-invasive ventilation, SMA, Interim, Gastroenteritis, SMN2, IV, Spinal muscular atrophy, Observational study, STRONG, Marketing, Dehydration, Survival, Clinical trial, Quality of life, Commonwealth of Australia (US securities entity), Research, Ventilation, Government, Sale, Walking, MD, Patient, Muscular Dystrophy Association, Regulation, Physician, Pandemic, Episcopal conference, Common, Viral, Diagnosis, MDA, Periodic breathing, Nationwide, Conference, Pneumonia, Safety, Disease, Birth control, Pharmaceutical industry, Nursing, Medical device, Sales, COVID-19, Novartis, Onasemnogene abeparvovec

“These children now have an improved quality of life, vastly different from what would have been expected for them if they had not received treatment.

Key Points: 
  • “These children now have an improved quality of life, vastly different from what would have been expected for them if they had not received treatment.
  • Results from the IV cohort, which included 63 patients, demonstrated how a single administration of Zolgensma provided consistent, substantial and durable efficacy over time.
  • “Data from the LT-001 and LT-002 studies showed that, regardless of the patient’s symptomatic status at the time of treatment, Zolgensma IV is an effective and durable treatment option.
  • Nor can there be any guarantee that such products will be commercially successful in the future.

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

Retrieved on: 
Saturday, March 18, 2023
DIN, Sodium chloride, Sepsis, Abscess, Health status of Asian Americans, Urinary tract infection, Pharmacy, Patient, Risk, Cystic fibrosis, Health, Health Canada, Glass, Pneumonia, Pharmaceutical industry, Medical device, Aztreonam

Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

Key Points: 
  • Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.
  • A cracked glass vial could cause potential injury or lead to potential contamination or a reduced dose.
  • Cayston is a prescription antibacterial medicine used for the management of chronic infections in cystic fibrosis patients.
  • The manufacturer has not received any customer complaints in relation to cracked glass vials in the recalled lots, or any other Cayston lots distributed in Canada.

GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults

Retrieved on: 
Tuesday, March 14, 2023
Education, Health, Consumer, Seniors, Other Health, General Health, Other Education, Multimedia, Pneumonia, MD, GSK plc, Hospital, Risk, Public health, Sideline, Chronic obstructive pulmonary disease, Ageing, CHF, GSK, RSV, COPD, Social media, Asthma, Immune system, Heart, Earvin, Bureau of Oceans and International Environmental and Scientific Affairs, Pharmaceutical industry, Vaccine

GSK plc (LSE/NYSE: GSK) has partnered with Earvin “Magic” Johnson to launch Sideline RSV , a new health education campaign aimed to help older adults and their loved ones better understand the risks and potential seriousness of RSV infection and how to help protect themselves.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) has partnered with Earvin “Magic” Johnson to launch Sideline RSV , a new health education campaign aimed to help older adults and their loved ones better understand the risks and potential seriousness of RSV infection and how to help protect themselves.
  • “My health is a top priority, yet like so many others, I was unaware that older adults are one of the highest risk groups for severe RSV infection, no matter how healthy they feel,” said Johnson.
  • In addition to Sideline RSV, Johnson will appear in a variety of educational content to highlight the risks of RSV in older adults, including those with certain underlying conditions.
  • “There is no vaccine or specific treatment available for RSV in older adults.

Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients

Retrieved on: 
Monday, March 13, 2023
Cystic fibrosis, CFTR, Cystic Fibrosis Foundation, Bacteria, Șaeș, Gallium, Pharmacokinetics, Associate, Pneumonia, Respiratory tract, European Medicines Agency, Doctor of Philosophy, EMA, PK, Johns Hopkins University, CF, MD, Patient, Pseudomonas aeruginosa, Food, Lung, Safety, Nature, FDA, Infection, LOS, FEV1, US Foods, Antibiotics, Pharmaceutical industry

LOS GATOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The study was conducted with funding support from the Cystic Fibrosis Foundation. AR-501 is being developed as a once-per-week inhaled dosing regimen that is self-administered using a commercially available nebulizer device.

Key Points: 
  • The study was conducted with funding support from the Cystic Fibrosis Foundation.
  • AR-501 is being developed as a once-per-week inhaled dosing regimen that is self-administered using a commercially available nebulizer device.
  • Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated in CF patients.
  • “Having met the primary and secondary endpoints of this study, we thank the Cystic Fibrosis Foundation for the tremendous support they’ve provided to help us complete this study” said Aridis’ CEO Vu Truong, PhD.

Sepsis - Pipeline Insight, 2022: Innovations from SciClone, Sanofi, BioAegis & More Set to Transform Sepsis Treatment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Health, Clinical Trials, Route, Protein, Cholesterol, COVID, Intensive care medicine, Infection, III, Therapy, Vaccine, Pneumonia, Cell, News, HCV, Clinical trial, Discovery, Bacterial pneumonia, Bacteria, Artery, Administration, Liver cancer, Patient, PCSK9, Risk, Heparin, Thymosin, Survival, Route of administration, Immunotherapy, Melanoma, Alirocumab, HBV, Cancer, Inflammation, LDL, Histone, Fungal infection, Hepatitis B virus, Pharmaceutical industry, Medical device, Sepsis

This "Sepsis- Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This "Sepsis- Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Atrium Health and Best Buy Health Partner to Improve Experience When Receiving Care at Home

Retrieved on: 
Tuesday, March 7, 2023
Technology, Managed Care, Hospitals, Family, Consumer, Other Retail, Wearables, Mobile Technology, Health, Health Technology, Specialty, Other Technology, Telemedicine, Virtual Medicine, Retail, Other Consumer, Seniors, Consumer Electronics, Online Retail, Rockcastle Regional Hospital and Respiratory Care Center, COPD, Infection, Pneumonia, Atrium Health, Vital signs, Telehealth, Patient, Partnership, Multimedia, Caregiver, COVID-19, Asthma, Nursing

Atrium Health and Best Buy Health are combining their strengths to develop new hospital at home offerings that will enhance the patient experience of receiving hospital-level care in the home.

Key Points: 
  • Atrium Health and Best Buy Health are combining their strengths to develop new hospital at home offerings that will enhance the patient experience of receiving hospital-level care in the home.
  • Atrium Health and Best Buy Health are teaming up to enhance the health system’s capabilities to provide hospital-quality care in patients’ homes using community paramedics, virtual visits with doctors and advanced wearable technology to monitor vital signs.
  • “We knew Atrium Health was the right partner to help tackle the unique challenges within the care at home experience,” said Deborah Di Sanzo, president of Best Buy Health.
  • Together with Best Buy Health, we will combine our strengths to provide better outcomes and equitable access for patients who will receive their care in the home.

Existing Chest Scans Offer New Opportunities for Predicting Surgical Risks

Retrieved on: 
Thursday, March 2, 2023
Survival, Doctor of Philosophy, Death, Stroke, NYU Langone Health, NYU, Woman, New York University Grossman School of Medicine, Research, Hospital, Patient, Plaque, National Institutes of Health, ACC, Bleeding, Bangladesh Technical Education Board, Risk, Heart, Department of Medicine – University of Pamplona, Splenic infarction, MS, Lung cancer, Record, Pneumonia, Radiology, Inflammation, Cardiology, Radiation exposure, MACE, Hand, American College, Blood, Physician, Medical imaging, Pharmaceutical industry, MD, Medicine

NEW YORK, March 2, 2023 /PRNewswire/ -- Instead of special heart scans, physicians can use images of the chest captured months earlier, and for other reasons, to estimate patients' risk of heart attack or death during several kinds of major surgeries, a new study shows.  

Key Points: 
  • Researchers at NYU Grossman School of Medicine analyzed existing computed tomography (CT) scans to estimate levels of hardened (calcified) fatty plaque deposits in the heart's three largest blood vessels.
  • Major surgeries, which usually involve vital organs, are known to put patients at risk for heart attack, stroke, and death.
  • To determine the risk of such events, physicians frequently recommend additional cardiac tests, which can delay surgery and increase healthcare costs.
  • The study authors realized, however, that many patients already have chest images from prior screenings for lung conditions like pneumonia and lung cancer.

Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Retrieved on: 
Wednesday, March 1, 2023
Infection, Medicine, Neck, Patient, Diagnosis, Weight loss, Leukopenia, Pain, Priority review, Prednisone, PMR, Disease, Shoulder, Fever, Risk, Regeneron Pharmaceuticals, Myalgia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, Inflammation, RA, Lifting, Neutropenia, Steroid, Pneumonia, Fatigue, Polymyalgia rheumatica, Flare, Food, Constipation, COVID-19, Pharmaceutical industry, Dietary supplement, Nursing, CS, Sanofi, Sarilumab

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

Key Points: 
  • "Polymyalgia rheumatica can be an incapacitating disease, causing painful disease flares in multiple parts of the body that leave people fatigued and unable to fully perform everyday activities.
  • Kevzara was previously approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.
  • Patients often experience flares during tapering of, or relapse after discontinuation of corticosteroid (CS) treatment.
  • Patients with PMR report difficulty in carrying out everyday functions such as getting out of bed, standing up from a chair, or lifting their arms.

ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus

Retrieved on: 
Tuesday, February 28, 2023
Viral, Influenza, Hand, Fibrosis, RSV, Disease, IND, Pressure, Lower respiratory tract infection, Patient, Bed, Bronchiolitis, Death, Infection, Pneumonia, Vaccine, COVID-19, OTCQB, Viral load, Tropical disease, H1N1

BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral diseases, and fibrosis announced today that in vitro testing at the Foundation for Neglected Disease Research (FNDR) in Bangalore India, showed that leading drug candidate ProLectin-M (PL-M) showed a significant reduction of viral load in influenza (H1N1) and in human Respiratory Syncytial Virus (RSV). The newest in vitro results, completed in early February 2023, are similar in nature to the SARS-CoV-2 test results that ultimately led to the successful completion of 2 clinical trials. The positive data and the non-toxic nature of the molecule justifies an IND filing to proceed to phase 2 human clinical trials.

Key Points: 
  • The positive data and the non-toxic nature of the molecule justifies an IND filing to proceed to phase 2 human clinical trials.
  • In December 2022 a wave of COVID-19, RSV, and Influenza infections hit all at once putting pressure on the hospital systems by maxing out the number of beds available.
  • Influenza has been infecting people worldwide since the 1500’s and the only way to control influenza is through the use of personal protective measures and frequent handwashing.
  • With this excellent in vitro data in hand from influenza and RSV, the Company anticipates it will add additional treatment arms to its COVID-19 studies.

Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia

Retrieved on: 
Tuesday, February 28, 2023
Infection, Death, Therapy, Protein, Principal, University, Mortality, Research, Cell, Pulmonary edema, Research fellow, University of Galway, Senior lecturer, Inflammation, IPS, Medical device, Messenger, Lung, Vaccine, Pneumonia

CAMBRIDGE, Mass., Feb. 28, 2023 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced the results of preclinical testing of aerosolized mRNA formulations currently under development for the treatment of pneumonia-associated lung inflammation. The study was led by Factor's collaborator, Dr. Daniel O'Toole, Senior Research Fellow, Senior Lecturer in Lung Regenerative Medicine and Principal Investigator in the CÚRAM and REMEDI institutes at the University of Galway.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2023 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced the results of preclinical testing of aerosolized mRNA formulations currently under development for the treatment of pneumonia-associated lung inflammation.
  • The ability to directly express anti-inflammatory proteins in lung tissue makes aerosolized mRNA an attractive candidate therapy for pneumonia.
  • "We are incredibly proud of our collaboration with CÚRAM, and are excited about the results of this study," said Dr. Christopher Rohde, Chief Technology Officer of Factor.
  • The results of this study were published last week in Nucleic Acid Therapeutics: https://doi.org/10.1089/nat.2022.0049